Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: aficamten
Trade Name: Myqorzo
Date Designated: 01/05/2021
Orphan Designation: Treatment of symptomatic hypertrophic cardiomyopathy
Orphan Designation Status: Designated/Approved
Cytokinetics Inc.
350 Oyster Point Blvd.
South San Francisco, California 94080
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: aficamten
Trade Name: Myqorzo
Marketing Approval Date: 12/19/2025
Approved Labeled Indication: treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms
Exclusivity End Date: TBD  
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-